<DOC>
	<DOCNO>NCT02854436</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety , pharmacokinetics niraparib men metastatic castration resistant prostate cancer ( mCRPC ) deoxyribonucleic acid ( DNA ) repair anomaly .</brief_summary>
	<brief_title>An Efficacy Safety Study Niraparib Men With Metastatic Castration-Resistant Prostate Cancer DNA-Repair Anomalies</brief_title>
	<detailed_description>This multicenter open-label ( participant researcher aware treatment participant receive ) study consist 4 phase ; Prescreening Phase biomarker evaluation , Screening Phase , Treatment Phase ( Cycle 1 Day 1 continue study drug discontinue ) , Follow-up Phase ( every 3 month end treatment visit ) . Participants monitor safety study period , 30 day last dose study drug .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Niraparib</mesh_term>
	<criteria>Histologically confirm prostate cancer ( mixed histology acceptable , exception small cell pure phenotype , exclude ) Disease progression treatment least 1 line taxanebased chemotherapy prostate cancer Disease progression treatment least 1 line Androgen Receptor ( AR ) target therapy Tumor Biomarkerpositive deoxyribonucleic acid ( DNA ) repair anomaly Progression metastatic prostate cancer set castrate level testosterone history bilateral orchiectomy study entry Prior treatment poly ( adenosine diphosphate [ ADP ] ribose ) polymerase ( PARP ) inhibitor Prior platinumbased chemotherapy treatment prostate cancer Known history current diagnosis myelodysplastic syndrome ( MDS ) /acute myeloid leukemia ( AML ) Known symptomatic impending cord compression Known symptomatic uncontrolled brain leptomeningeal metastasis ( Day 1 )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>CRPC</keyword>
	<keyword>Metastatic castrate-resistant prostate cancer</keyword>
	<keyword>Prostate neoplasm</keyword>
	<keyword>Galahad</keyword>
	<keyword>Niraparib</keyword>
	<keyword>DNA anomaly</keyword>
	<keyword>DNA defect</keyword>
	<keyword>PARP inhibitor</keyword>
	<keyword>PARPi</keyword>
</DOC>